A Sonablate HIFU physician can completely customize a patient’s treatment plan based on real-time tissue response, tissue density and location of significant structures. Competitive devices are limited to three pre-set power levels that cannot be changed once treatment has begun.
The Sonablate® 500 system incorporates the latest customized treatment and safety technologies in an attempt to strike a balance that has been difficult to achieve in prostate cancer treatment-increasing disease control capabilities while decreasing quality-of-life side effect risks.
Sonablate HIFU technology allows for smaller lesion size and ability to take care of larger prostate without an advance surgical procedure known as a TURP. The Sonablate 500 creates a 10-12mm lesion, which conforms optimally around vital structures, allowing for complete tissue ablation throughout the gland and decreased risk for untreated tissue remaining. The competing device creates a 16-24 mm lesion, which compromises the treatment around smaller critical spaces, which may end up in tissue being left untreated. Due to the lesion size, treatment protocol states a 4-8mm “safety zone” must be left untreated, again potentially leaving cancer cells behind.
Patients with approximately a 40 gram prostate may be treated with Sonablate HIFU without receiving a surgical procedure often known as a TURP to decrease its volume. The competing device treats prostates of up to 24 grams in volume without a TURP; patients with larger glands up to 40 grams must first undergo a TURP.
# # #
Dr. Richard R. Lotenfoe is the Founder of Urology Health Solutions Inc., and CEO of Innovative Technologies, LLC, and is regarded by many of his fellow surgeons as a pioneer in Urology in the State of Florida and the United States. Since establishing his Florida practice in 1999, he has been firmly committed to embracing minimally invasive technology and perfecting the latest urological surgical techniques.